FDA Clearance Tracker · DEN190025
OraQuick Ebola Rapid Antigen Test
Last checked: Nov 19, 2026Latest source record: Oct 10, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Oct 10, 2019
De Novo granted
Time to decision
150 days
Received May 13, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN190025
- Device name
- OraQuick Ebola Rapid Antigen Test
- Applicant
- OraSure Technologies, Inc.
- Applicant location
- Bethlehem, PA
- Received
- May 13, 2019
- Decided
- Oct 10, 2019
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device type
- Device To Detect Antigens Of Biothreat Microbial Agents In Human Clinical Specimens (QID)
- Device class
- Class II
- Regulation
- 21 CFR 866.4002
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN190025
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for OraSure Technologies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.